[{"id":"b7c5654f-af40-4901-bb91-a92eb186ae23","acronym":"TURBO","url":"https://clinicaltrials.gov/study/NCT06111417","created_at":"2023-11-01T15:12:33.488Z","updated_at":"2025-02-25T14:10:16.182Z","phase":"","brief_title":"Use of an Ultra-rapid BRCA1/2 Status Screening Test in Theranostic Indication: Performance and Interest for Patients and Practitioners","source_id_and_acronym":"NCT06111417 - TURBO","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/12/2024","start_date":" 06/12/2024","primary_txt":" Primary completion: 06/12/2026","primary_completion_date":" 06/12/2026","study_txt":" Completion: 08/12/2026","study_completion_date":" 08/12/2026","last_update_posted":"2025-02-18"},{"id":"aabfe14b-2567-4902-bc32-9cee3990645a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03317405","created_at":"2021-01-18T16:22:58.685Z","updated_at":"2025-02-25T14:39:46.434Z","phase":"Phase 1","brief_title":"Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery","source_id_and_acronym":"NCT03317405","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 02/22/2021","primary_completion_date":" 02/22/2021","study_txt":" Completion: 08/16/2025","study_completion_date":" 08/16/2025","last_update_posted":"2025-02-14"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"79754c99-3751-46a3-9cbb-21442fd0c3e5","acronym":"NRG-GY023","url":"https://clinicaltrials.gov/study/NCT04739800","created_at":"2021-02-05T13:56:26.400Z","updated_at":"2025-02-25T15:26:41.757Z","phase":"Phase 2","brief_title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","source_id_and_acronym":"NCT04739800 - NRG-GY023","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["PD-L1 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/10/2021","start_date":" 06/10/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 06/14/2025","study_completion_date":" 06/14/2025","last_update_posted":"2025-02-10"},{"id":"b328f4e5-105e-4a5c-a45f-4777aede9baa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457257","created_at":"2022-07-13T11:56:53.469Z","updated_at":"2025-02-25T16:17:55.903Z","phase":"Phase 4","brief_title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","source_id_and_acronym":"NCT05457257","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Xtandi (enzalutamide) • abiraterone acetate • prednisone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/29/2022","start_date":" 07/29/2022","primary_txt":" Primary completion: 10/22/2024","primary_completion_date":" 10/22/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-07"},{"id":"849f2903-a63e-4422-bd1f-c14fc38ea333","acronym":"BGB-290-102","url":"https://clinicaltrials.gov/study/NCT03333915","created_at":"2021-01-17T17:46:43.275Z","updated_at":"2025-02-25T16:52:02.784Z","phase":"Phase 1/2","brief_title":"Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT03333915 - BGB-290-102","lead_sponsor":"BeiGene","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Partruvix (pamiparib)"],"overall_status":"Completed","enrollment":" Enrollment 128","initiation":"Initiation: 12/21/2016","start_date":" 12/21/2016","primary_txt":" Primary completion: 08/24/2020","primary_completion_date":" 08/24/2020","study_txt":" Completion: 08/11/2021","study_completion_date":" 08/11/2021","last_update_posted":"2025-02-04"},{"id":"074f4f72-e179-49af-b9d4-a6b1faee4ca3","acronym":"NRG-GY021","url":"https://clinicaltrials.gov/study/NCT04034927","created_at":"2021-01-18T19:48:04.192Z","updated_at":"2025-02-25T17:00:08.274Z","phase":"Phase 2","brief_title":"Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer","source_id_and_acronym":"NCT04034927 - NRG-GY021","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 12/04/2019","start_date":" 12/04/2019","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-03"},{"id":"e67c4121-e4a3-4176-8769-d4c34dab965a","acronym":"SOLO-2","url":"https://clinicaltrials.gov/study/NCT01874353","created_at":"2021-01-17T17:30:02.561Z","updated_at":"2025-02-25T16:13:13.271Z","phase":"Phase 3","brief_title":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","source_id_and_acronym":"NCT01874353 - SOLO-2","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 327","initiation":"Initiation: 09/03/2013","start_date":" 09/03/2013","primary_txt":" Primary completion: 09/19/2016","primary_completion_date":" 09/19/2016","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-29"},{"id":"bf66f941-6a2a-46d7-85ee-195ce47af690","acronym":"OlympiAD","url":"https://clinicaltrials.gov/study/NCT02000622","created_at":"2021-01-17T17:37:41.420Z","updated_at":"2025-02-25T16:13:35.803Z","phase":"Phase 3","brief_title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","source_id_and_acronym":"NCT02000622 - OlympiAD","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • capecitabine • Halaven (eribulin mesylate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 302","initiation":"Initiation: 03/27/2014","start_date":" 03/27/2014","primary_txt":" Primary completion: 12/09/2016","primary_completion_date":" 12/09/2016","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-20"},{"id":"eccae38b-1886-4206-b6f1-ab2c523e9706","acronym":"BAROCCO","url":"https://clinicaltrials.gov/study/NCT03314740","created_at":"2021-01-18T16:22:11.917Z","updated_at":"2025-02-25T14:58:26.251Z","phase":"Phase 2","brief_title":"Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib","source_id_and_acronym":"NCT03314740 - BAROCCO","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • paclitaxel • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 06/12/2017","start_date":" 06/12/2017","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2025-01-10"},{"id":"063a0064-5caa-408a-8c70-d7f6a82b7af1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02953457","created_at":"2021-01-18T14:30:22.179Z","updated_at":"2025-02-25T15:07:19.264Z","phase":"Phase 2","brief_title":"Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation","source_id_and_acronym":"NCT02953457","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/29/2017","start_date":" 06/29/2017","primary_txt":" Primary completion: 09/15/2021","primary_completion_date":" 09/15/2021","study_txt":" Completion: 08/15/2024","study_completion_date":" 08/15/2024","last_update_posted":"2024-11-19"},{"id":"28c1fd40-f94e-4cca-b4b5-626fe1cac96a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04673448","created_at":"2021-01-19T20:45:05.881Z","updated_at":"2025-02-25T13:19:47.405Z","phase":"Phase 1","brief_title":"Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT04673448","lead_sponsor":"University of Washington","biomarkers":" HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2024-11-08"},{"id":"8cb4234f-c738-4083-b46f-8fc3430135ea","acronym":"ComPAKT","url":"https://clinicaltrials.gov/study/NCT02338622","created_at":"2021-01-17T17:26:12.811Z","updated_at":"2025-02-25T15:06:26.078Z","phase":"Phase 1","brief_title":"Trial of Olaparib in Combination with AZD5363 (ComPAKT)","source_id_and_acronym":"NCT02338622 - ComPAKT","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" BRCA1 • BRCA2 • PARP1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • PARP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Truqap (capivasertib)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 03/31/2014","start_date":" 03/31/2014","primary_txt":" Primary completion: 03/21/2016","primary_completion_date":" 03/21/2016","study_txt":" Completion: 03/21/2017","study_completion_date":" 03/21/2017","last_update_posted":"2024-09-26"},{"id":"b5da7b4a-4908-4f45-9515-2de24f2647c5","acronym":"OlympiA","url":"https://clinicaltrials.gov/study/NCT02032823","created_at":"2021-01-18T09:19:21.347Z","updated_at":"2025-02-25T16:13:42.703Z","phase":"Phase 3","brief_title":"Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer","source_id_and_acronym":"NCT02032823 - OlympiA","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • PGR positive","tags":["HER-2 • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1837","initiation":"Initiation: 04/22/2014","start_date":" 04/22/2014","primary_txt":" Primary completion: 03/27/2020","primary_completion_date":" 03/27/2020","study_txt":" Completion: 05/28/2029","study_completion_date":" 05/28/2029","last_update_posted":"2024-08-23"},{"id":"46b92c9c-5eb9-4b3d-9d5e-c35458db6080","acronym":"1-2018 BSMO","url":"https://clinicaltrials.gov/study/NCT03967938","created_at":"2021-01-18T19:31:16.051Z","updated_at":"2025-02-25T15:08:35.426Z","phase":"Phase 2","brief_title":"Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes","source_id_and_acronym":"NCT03967938 - 1-2018 BSMO","lead_sponsor":"AZ-VUB","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 540","initiation":"Initiation: 02/07/2019","start_date":" 02/07/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-08-19"},{"id":"45278662-36a8-4fe3-8690-2d8d82a1f451","acronym":"","url":"https://clinicaltrials.gov/study/NCT05841563","created_at":"2023-05-03T15:04:56.483Z","updated_at":"2024-07-02T16:34:26.037Z","phase":"Phase 1","brief_title":"Clinical Trial of PM54 in Advanced Solid Tumors Patients.","source_id_and_acronym":"NCT05841563","lead_sponsor":"PharmaMar","biomarkers":" BRAF • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • BRAF mutation • BRAF wild-type","tags":["BRAF • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PM54"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 04/28/2023","start_date":" 04/28/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-06-14"},{"id":"547414d8-facd-47ac-bdb8-a247edecacd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00043472","created_at":"2021-01-18T00:03:35.293Z","updated_at":"2024-07-02T16:34:25.754Z","phase":"","brief_title":"Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk","source_id_and_acronym":"NCT00043472","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 07/09/2003","start_date":" 07/09/2003","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-06-14"},{"id":"9a54d64d-2889-431d-bba8-38823f83de86","acronym":"","url":"https://clinicaltrials.gov/study/NCT05922930","created_at":"2023-06-28T14:08:31.873Z","updated_at":"2024-07-02T16:34:25.851Z","phase":"Phase 1/2","brief_title":"Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer","source_id_and_acronym":"NCT05922930","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • TACSTD2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • TROP2 expression","tags":["BRCA1 • BRCA2 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • TROP2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TROP2-CAR-NK"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-06-14"},{"id":"6a0cd4a1-906c-4468-b9bf-fae916dc7b2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05287451","created_at":"2022-03-18T11:54:35.018Z","updated_at":"2024-07-02T16:34:26.864Z","phase":"","brief_title":"Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study","source_id_and_acronym":"NCT05287451","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • BRIP1 • RAD51C • RAD51D","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • BRIP1 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/10/2022","start_date":" 05/10/2022","primary_txt":" Primary completion: 12/26/2026","primary_completion_date":" 12/26/2026","study_txt":" Completion: 12/26/2026","study_completion_date":" 12/26/2026","last_update_posted":"2024-06-12"},{"id":"81538df4-516d-49a5-ada8-8fcdc290500e","acronym":"NCI 9938","url":"https://clinicaltrials.gov/study/NCT02595931","created_at":"2021-07-05T16:47:22.525Z","updated_at":"2024-07-02T16:34:37.311Z","phase":"Phase 1","brief_title":"M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02595931 - NCI 9938","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 07/22/2016","start_date":" 07/22/2016","primary_txt":" Primary completion: 03/07/2023","primary_completion_date":" 03/07/2023","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2024-06-07"},{"id":"e0d150b0-e8da-41e4-9df7-1fc41df6dcb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02484404","created_at":"2021-01-17T17:57:31.886Z","updated_at":"2024-07-02T16:34:36.994Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...","source_id_and_acronym":"NCT02484404","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation","tags":["EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 384","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-06-07"},{"id":"4151ec9e-af4a-4950-bf53-3592b2000539","acronym":"","url":"https://clinicaltrials.gov/study/NCT05866679","created_at":"2023-05-19T13:04:53.778Z","updated_at":"2024-07-02T16:34:59.326Z","phase":"Phase 1","brief_title":"Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging","source_id_and_acronym":"NCT05866679","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • MSH2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/12/2024","start_date":" 04/12/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-06-04"},{"id":"543cd16b-633b-4c4e-b967-73fb1131c4b4","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT03845296","created_at":"2021-01-17T17:13:03.964Z","updated_at":"2024-07-02T16:34:59.337Z","phase":"Phase 2","brief_title":"Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT03845296 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4","pipe":" | ","alterations":" BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation","tags":["EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-04"},{"id":"80d058fa-b19a-4e22-b59d-ca59b8425b25","acronym":"","url":"https://clinicaltrials.gov/study/NCT04991480","created_at":"2021-08-05T13:53:03.393Z","updated_at":"2024-07-02T16:34:59.371Z","phase":"Phase 1","brief_title":"A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04991480","lead_sponsor":"Artios Pharma Ltd","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Zejula (niraparib) • ART4215"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-06-03"}]